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Background
Developing a safe and effective HIV-1 vaccine has been
hampered by the inability to design immunogens that can
induce antibodies capable of potently neutralizing diverse
HIV-1 strains. Despite the recognition of conserved HIV-1
envelope (Env) regions by rare, broadly neutralizing anti-
bodies, these regions fail to induce protective antibodies
when used as immunogens or in the context of natural
infections. Various hypotheses have been offered to
explain the absence of an effective immune response to
Env determinants, including the suppression of this
response by immunological tolerance. This hypothesis
arose from the observation that broadly neutralizing HIV-
1 antibodies can cross-react with self-antigens.
Methods
To test the tolerance hypothesis, we generated a knock-in
mouse strain, 2F5 VH, in which the immunoglobulin (Ig)
heavy chain variable region rearrangement (VHDHJH) of
the broadly neutralizing human antibody 2F5 was tar-
geted into the JH cluster of the mouse Igh locus.
Results
In vitro, chimeric human/mouse 2F5 antibodies were
functionally equivalent to the human 2F5 antibody. In
vivo, the 2F5 VH insertion resulted in a profound B cell
developmental blockade in the bone marrow with >80%
loss of immature B cells. Furthermore, both 2F5 
and 2F5   mice lacked serum reactivity to cardiolipin
and nuclear antigens, yet had detectable, albeit severely
diminished, mature splenic B cell populations. In 2F5
 mice, the majority of remaining mature splenic B
cells used endogenous heavy chains, indicating loss of
effective allelic exclusion.
Conclusion
The 2F5 VH knock-in phenotype identifies a profound
effect of tolerance mechanisms on suppressing 2F5 anti-
body heavy chain-expressing B cells, and is similar to that
seen in other knock-in strains expressing Ig heavy chains
of autoreactive antibodies. This mouse strain will be use-
ful for developing immunization strategies to circumvent
tolerance mechanisms and safely induce broadly neutral-
izing antibodies against the gp41 membrane proximal
external region.
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